Pricing needs to balance the 'full scope' of responsibility, and reality

July 1, 2020 Comment

This is a preview of subscriber content

Subscribe now to continue reading.

Pharmaceutical companies are not charities. They use shareholder funds to invest in R&D with the goal of developing what need to be commercially viable products. This is a basic principle that some seem not to understand, or conveniently choose not to understand. …

Subscribe now to continue reading.

Latest Video

Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - Latest News
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - Latest News
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - Latest News
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - Latest News
Syntara launches Phase 2 trial aiming to reduce transfusion burden in myelodysplastic syndromes
November 22, 2025

Pricing needs to balance the 'full scope' of responsibility, and reality

This is a preview of subscriber content

Latest Video

Most Read

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

A scrapped website, almost $100 million, and the politics of what really matters

New national report warns of deepening ovarian cancer burden and calls for urgent action

Syntara launches Phase 2 trial aiming to reduce transfusion burden in myelodysplastic syndromes

New Stories

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial

New review recommends a balanced and measured approach to adopting AI in clinical practice

Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions

Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action

Sign In

Pricing needs to balance the 'full scope' of responsibility, and reality

This is a preview of subscriber content

Latest Video

Most Read

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

A scrapped website, almost $100 million, and the politics of what really matters

New national report warns of deepening ovarian cancer burden and calls for urgent action

Syntara launches Phase 2 trial aiming to reduce transfusion burden in myelodysplastic syndromes

Follow Us

New Stories

NSW Premier opens Australia’s first large-scale health translation hub at UNSW

Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial

New review recommends a balanced and measured approach to adopting AI in clinical practice

Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions

Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow

‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma

New national report warns of deepening ovarian cancer burden and calls for urgent action